Valuation: Simulations Plus

Market Cap 37Cr 34Cr 31Cr 28Cr 53Cr 3.48TCr 56Cr 379.39Cr 150.49Cr 1.88TCr 139.61Cr 136.69Cr 5.95TCr P/E 2024
74x
P/E 2025 -4.4x
Enterprise Value 34Cr 31Cr 29Cr 26Cr 49Cr 3.18TCr 51Cr 347.03Cr 137.66Cr 1.72TCr 127.71Cr 125.03Cr 5.44TCr EV / Sales 2024
10.1x
EV / Sales 2025 3.2x
Free-Float
99.59%
Yield 2024
0.66%
Yield 2025 -
3 months+0.71%
6 months+31.21%
Current year+1.48%
Current year 11.09
Extreme 11.09
21.01
1 year 11.09
Extreme 11.09
21.01
3 years 11.09
Extreme 11.09
51.22
5 years 11.09
Extreme 11.09
67.59
10 years 8.81
Extreme 8.81
90.92
Manager TitleAgeSince
Chief Executive Officer 67 26/06/2018
Director of Finance/CFO 63 01/12/2020
Chief Tech/Sci/R&D Officer - -
Date Insider Type Main position Quantity % Market Cap. Importance
06/10/26 Issuer sale

Chairman

-23,547 0.1169%
06/10/26 Issuer sale

Chief Financial Officer

-1,09,600 0.5440%
06/10/26 Issuer sale

Founder

-32,07,131 15.9190%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%+13.36%-52.66% 37Cr
-0.58%-1.53%+20.04%+47.67% 26TCr
-0.45%-1.98%+2.32%+9.52% 16TCr
-3.26%-7.42%-27.88%+33.40% 14TCr
-1.49%-2.74%-55.68%-20.89% 6.23TCr
-1.28%-1.81%+20.76%+55.28% 5.97TCr
-1.38%-1.75%+4.58%-13.64% 5.35TCr
-1.12%+1.35%+21.43%+54.96% 4.94TCr
-2.06%-1.24%+21.32%+74.31% 4.49TCr
-5.15%-13.06%-3.69%+48.93% 4.26TCr
Average -1.22%-2.96%+1.65%+23.69% 9TCr
Weighted average by Cap. -0.84%-3.60%+1.64%+31.97%

Financials

2024 2025
Net sales 7Cr 6.38Cr 5.9Cr 5.34Cr 10Cr 653.88Cr 10Cr 71Cr 28Cr 353.34Cr 26Cr 26Cr 1.12TCr 7.92Cr 7.21Cr 6.68Cr 6.04Cr 11Cr 739.49Cr 12Cr 81Cr 32Cr 399.6Cr 30Cr 29Cr 1.27TCr
Net income 99.54L 90.69L 83.95L 75.94L 1.42Cr 93Cr 1.49Cr 10Cr 4.03Cr 50Cr 3.73Cr 3.66Cr 159.13Cr -6.47Cr -5.9Cr -5.46Cr -4.94Cr -9.26Cr -604.43Cr -9.69Cr -66Cr -26Cr -326.62Cr -24Cr -24Cr -1.03TCr
Net Debt -1.92Cr -1.75Cr -1.62Cr -1.47Cr -2.75Cr -179.77Cr -2.88Cr -20Cr -7.78Cr -97Cr -7.22Cr -7.07Cr -307.73Cr -3.17Cr -2.89Cr -2.68Cr -2.42Cr -4.54Cr -296.41Cr -4.75Cr -32Cr -13Cr -160.17Cr -12Cr -12Cr -507.37Cr
Projected Income Statement - Annual - Simulations Plus
Logo Simulations Plus
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
Employees
213
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Simulations Plus